An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system.
Calcitonin gene related peptide (CGRP) released from the C-fibers projecting from the trigeminal ganglion to the meninges has been suggested to play a crucial role in the pathophysiology of headache, particularly migraine. In humans it has been shown that CGRP is released during migraine-attacks, and this is attenuated by the administration of typical anti-migraine drugs such as dihydroergotamine or sumatriptan. We describe a new rat model which allows the study of CGRP release from the meninges into venous blood following activation of the trigeminal vascular system. The effects of classical and new anti-migraine drugs such as acetylsalicylic acid (ASA), sumatriptan and the new high efficacy 5-HT1B/1D agonist donitriptan (4-[4-[2-(2-aminoethyl)-1H-indol-5-yloxyl]acetyl]piperazinyl-1-yl]benzonitrile) were evaluated in comparison with the established model of neurogenic inflammation in the meninges. Sumatriptan and donitriptan inhibited CGRP release as well as neurogenic inflammation. ASA, however, attenuated neurogenic inflammation, but not CGRP release, confirming the concept of prejunctional inhibition of CGRP release by 5-HT1B/1D receptors. This new model allows the further study of prejunctional pharmacology and mechanisms of neuropeptide release in the trigeminal vascular system, which might be crucial for the further development of potent, more effective anti-migraine drugs.
Limmroth
V
V
Department of Neurology, University of Essen, Essen, Germany. volker.limmroth@uni-essen.de
Katsarava
Z
Z
Liedert
B
B
Guehring
H
H
Schmitz
K
K
Diener
H C
HC
Michel
M C
MC
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism*; D004195:Disease Models, Animal; D008297:Male; D008578:Meninges / Q000378:metabolism; D008881:Migraine Disorders / Q000188:drug therapy / Q000378:metabolism*; D009412:Nerve Fibers / Q000378:metabolism; D009437:Neuralgia / Q000188:drug therapy / Q000378:metabolism; D009570:Nitriles / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018170:Sumatriptan / Q000494:pharmacology; D012668:Trigeminal Ganglion / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism*; D014363:Tryptamines; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D009570:Nitriles; D010879:Piperazines; D014363:Tryptamines; D014662:Vasoconstrictor Agents; C120143:donitriptan; D018170:Sumatriptan; D015740:Calcitonin Gene-Related Peptide; D001241:Aspirin